249 related articles for article (PubMed ID: 11593331)
1. Prostate-specific targeting using PSA promoter-based lentiviral vectors.
Yu D; Chen D; Chiu C; Razmazma B; Chow YH; Pang S
Cancer Gene Ther; 2001 Sep; 8(9):628-35. PubMed ID: 11593331
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen promoter/enhancer driven gene therapy for prostate cancer: construction and testing of a tissue-specific adenovirus vector.
Latham JP; Searle PF; Mautner V; James ND
Cancer Res; 2000 Jan; 60(2):334-41. PubMed ID: 10667585
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
[TBL] [Abstract][Full Text] [Related]
4. Targeting and eradicating cancer cells by a prostate-specific vector carrying the diphtheria toxin A gene.
Pang S
Cancer Gene Ther; 2000 Jul; 7(7):991-6. PubMed ID: 10917201
[TBL] [Abstract][Full Text] [Related]
5. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A.
Zheng JY; Chen D; Chan J; Yu D; Ko E; Pang S
Cancer Gene Ther; 2003 Oct; 10(10):764-70. PubMed ID: 14502229
[TBL] [Abstract][Full Text] [Related]
6. Tightly-regulated suicide gene expression kills PSA-expressing prostate tumor cells.
Peng W; Chen J; Huang YH; Sawicki JA
Gene Ther; 2005 Nov; 12(21):1573-80. PubMed ID: 16034457
[TBL] [Abstract][Full Text] [Related]
7. Prostate-tumor targeting of gene expression by lentiviral vectors containing elements of the probasin promoter.
Yu D; Jia WW; Gleave ME; Nelson CC; Rennie PS
Prostate; 2004 Jun; 59(4):370-82. PubMed ID: 15065085
[TBL] [Abstract][Full Text] [Related]
8. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
9. Use of the PSA enhancer core element to modulate the expression of prostate- and non-prostate-specific basal promoters in a lentiviral vector context.
Chapel-Fernandes S; Jordier F; Lauro F; Maitland N; Chiaroni J; de Micco P; Mannoni P; Bagnis C
Cancer Gene Ther; 2006 Oct; 13(10):919-29. PubMed ID: 16741521
[TBL] [Abstract][Full Text] [Related]
10. Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
Lee SE; Jin RJ; Lee SG; Yoon SJ; Park MS; Heo DS; Choi H
Anticancer Res; 2000; 20(1A):417-22. PubMed ID: 10769689
[TBL] [Abstract][Full Text] [Related]
11. Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations.
Suzuki S; Tadakuma T; Asano T; Hayakawa M
Cancer Res; 2001 Feb; 61(4):1276-9. PubMed ID: 11245419
[TBL] [Abstract][Full Text] [Related]
12. Development of prostate-specific antigen promoter-based gene therapy for androgen-independent human prostate cancer.
Gotoh A; Ko SC; Shirakawa T; Cheon J; Kao C; Miyamoto T; Gardner TA; Ho LJ; Cleutjens CB; Trapman J; Graham FL; Chung LW
J Urol; 1998 Jul; 160(1):220-9. PubMed ID: 9628654
[TBL] [Abstract][Full Text] [Related]
13. [Establishment of RNA interfering retrovirus vector targeting CXCR4 gene driven by human prostate-specific antigen promoter and its biological effects on prostate cancer cells].
Du YF; Xing YF; Zeng FQ; Lu P; Liu XY; Xiao YJ
Zhonghua Zhong Liu Za Zhi; 2007 Jul; 29(7):489-94. PubMed ID: 18069626
[TBL] [Abstract][Full Text] [Related]
14. Gene transfer in ovarian cancer cells: a comparison between retroviral and lentiviral vectors.
Indraccolo S; Habeler W; Tisato V; Stievano L; Piovan E; Tosello V; Esposito G; Wagner R; Uberla K; Chieco-Bianchi L; Amadori A
Cancer Res; 2002 Nov; 62(21):6099-107. PubMed ID: 12414634
[TBL] [Abstract][Full Text] [Related]
15. Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells.
Lowe SL; Rubinchik S; Honda T; McDonnell TJ; Dong JY; Norris JS
Gene Ther; 2001 Sep; 8(18):1363-71. PubMed ID: 11571575
[TBL] [Abstract][Full Text] [Related]
16. A complex adenovirus vector that delivers FASL-GFP with combined prostate-specific and tetracycline-regulated expression.
Rubinchik S; Wang D; Yu H; Fan F; Luo M; Norris JS; Dong JY
Mol Ther; 2001 Nov; 4(5):416-26. PubMed ID: 11708878
[TBL] [Abstract][Full Text] [Related]
17. Human prostate cancer progression models and therapeutic intervention.
Chung LW; Kao C; Sikes RA; Zhau HE
Hinyokika Kiyo; 1997 Nov; 43(11):815-20. PubMed ID: 9436028
[TBL] [Abstract][Full Text] [Related]
18. Chimeric PSA enhancers exhibit augmented activity in prostate cancer gene therapy vectors.
Wu L; Matherly J; Smallwood A; Adams JY; Billick E; Belldegrun A; Carey M
Gene Ther; 2001 Sep; 8(18):1416-26. PubMed ID: 11571582
[TBL] [Abstract][Full Text] [Related]
19. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
Karr JF; Kantor JA; Hand PH; Eggensperger DL; Schlom J
Cancer Res; 1995 Jun; 55(11):2455-62. PubMed ID: 7538903
[TBL] [Abstract][Full Text] [Related]
20. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
